Diabetic Retinal Disease Rates Narrow by Diabetes Type - Scorecard - MDSpire
Advertisement
Diabetic Retinal Disease Rates Narrow by Diabetes Type
US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.
Clinical Scorecard: Diabetic Retinal Disease Rates Narrow by Diabetes Type
At a Glance
Category
Detail
Condition
Diabetic Retinal Disease (DRD), including vision-threatening forms (VTDR), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR)
Key Mechanisms
Microvascular complications of diabetes affecting the retina, with prevalence and incidence influenced by diabetes type and disease management
Target Population
Patients with type 1 and type 2 diabetes in the United States
Care Setting
Outpatient and specialty care settings managing diabetic complications
Key Highlights
Prevalence of DRD increased from 2016 to 2021 in both type 1 and type 2 diabetes, with type 1 diabetes consistently showing higher rates.
Incidence of overall DRD declined in type 1 diabetes and approached rates seen in type 2 diabetes by 2022, narrowing the incidence gap.
Incidence of severe DRD subtypes (VTDR, DME, PDR) remained higher in type 1 diabetes, with some disparities widening, particularly for PDR.
Guideline-Based Recommendations
Diagnosis
Use validated ICD codes for identifying diabetic retinal disease and its subtypes in administrative data.
Recognize higher prevalence and incidence of DRD in type 1 diabetes patients compared to type 2 diabetes.
Management
Implement advances in diabetes care to reduce incidence of DRD, especially in type 1 diabetes.
Monitor and manage vision-threatening complications such as DME and PDR proactively.
Monitoring & Follow-up
Regular retinal screening for all patients with diabetes, with heightened vigilance in type 1 diabetes due to higher risk.
Track changes in DRD prevalence and incidence to adjust care strategies accordingly.
Risks
Longer diabetes duration and complications increase DRD prevalence.
Differences in disease subtype incidence suggest need for tailored monitoring and intervention.
Patient & Prescribing Data
3,682,484 patients with diabetes (101,579 type 1 diabetes; 3,580,905 type 2 diabetes) covered by commercial insurance and Medicare Advantage plans in the US
Declining incidence of DRD in type 1 diabetes may reflect improved diabetes management; however, persistent higher rates of severe DRD subtypes warrant continued targeted interventions.
Clinical Best Practices
Maintain regular retinal screening schedules for both type 1 and type 2 diabetes patients.
Focus on early detection and treatment of VTDR, DME, and PDR to prevent vision loss.
Consider the narrowing incidence gap when planning resource allocation but recognize persistent higher burden in type 1 diabetes.
Use administrative claims data cautiously, acknowledging limitations such as lack of clinical detail and potential impact of healthcare utilization changes.
